drugset

drugset / Trial / NCT02965118

CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis

NCT02965118 ↗

Phase 3 Completed 240 enrolled Amorepacific Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase III study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.

Timeline

Start: 2016-11
Primary completion: 2018-11
Completion: 2018-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PAC-14028	Unknown	1 %	Topical

Indications